SLC22A16 and breast carcinoma: This result is concordant with the findings of Bray et al. [10], who observed lower incidence of dose delay, caused by leukopenia and neutropenia, of doxorubicin/cyclophosphamide chemotherapy in breast cancer patients for several SNPs in SLC22A16, including p.Asn104=.